MCID: HYP073
MIFTS: 44

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 15
Immunoproliferative Disorders 43 71
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
MeSH 43 D007160
SNOMED-CT 67 127071007
ICD10 32 C88 C88.9
UMLS 71 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

Disease Ontology : 12 A hypersensitivity reaction disease that is characterized by a cell-mediated response to antigens, where Th1 helper T cells react with antigens on antigen-presenting cells and cause a delayed type immune response.

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to cryoglobulinemia and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Fludarabine and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and myeloid, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 756)
# Related Disease Score Top Affiliating Genes
1 cryoglobulinemia 33.1 TNF IL10 IFNG CD40LG
2 autoimmune lymphoproliferative syndrome 32.4 TNF MAS1L IL2 IL10 ICOSLG CD8A
3 sarcoidosis 1 32.0 TNFRSF1B TNF SERPINA3 NOD2 MIR155 IL2
4 lymphoma, mucosa-associated lymphoid type 31.3 ICOSLG CD40LG CD4 CCR6
5 amyloidosis 31.1 TNF SERPINA3 CRP CD40LG
6 monoclonal gammopathy of uncertain significance 31.0 TNF ICOSLG CD40LG CCR6
7 post-transplant lymphoproliferative disease 31.0 TNFRSF1B TNF IL10
8 lymphoma, hodgkin, classic 30.9 MIR155 IL2 ICOSLG CCR6
9 duodenitis 30.8 TNF CRP CD8A CD40LG CD4
10 polyneuropathy 30.8 TNF CRP CD40LG ACE
11 intestinal disease 30.7 TNF SERPINA3 NOD2 MIR155 IL10 ICOSLG
12 leukemia, chronic lymphocytic 30.7 TNF MIR155 IL2 IL10 ICOSLG CD8A
13 myeloma, multiple 30.6 TNF SERPINA3 IL2 IL10 IFNG ICOSLG
14 immune deficiency disease 30.4 TNF SERPINA3 IL2 IL10 IFNG ICOSLG
15 crohn's disease 30.2 TNFRSF1B TNF NOD2 IL2 IL10 IFNG
16 lymphoma, non-hodgkin, familial 30.1 TNFRSF1B TNF SERPINA3 MIR155 IL2 IL10
17 heavy chain disease 11.4
18 schnitzler syndrome 11.4
19 chronic nk-cell lymphocytosis 11.4
20 alpha chain disease 10.9
21 histoplasmosis meningitis 10.8 CD40LG ACE
22 histoplasmosis pericarditis 10.8 TNF ACE
23 alpha-heavy chain disease 10.8
24 adult acute lymphocytic leukemia 10.8 CD8A CD4 CCR6
25 cork-handlers' disease 10.8 CD8A CD40LG CD4
26 uveoparotid fever 10.8 TNF CD8A ACE
27 mediastinum teratoma 10.8 CRP ACE
28 chancroid 10.8 CD40LG CD4 CCR6
29 autoimmune peripheral neuropathy 10.8 ICOSLG CD40LG CD4
30 early yaws 10.8 CD8A CD40LG CD4
31 diabetes mellitus, insulin-dependent, 23 10.7 TNF CD8A CD4
32 esophageal candidiasis 10.7 CD8A CD4 CCR6
33 punctate inner choroidopathy 10.7 TNF IL10
34 norwegian scabies 10.7 CD8A CD40LG CD4
35 autoimmune neuropathy 10.7 ICOSLG CD40LG CD4
36 brawny scleritis 10.7 IFNG CD40LG ACE
37 acute retinal necrosis syndrome 10.7 CD8A CD40LG CD4
38 west nile encephalitis 10.7 CD8A CD40LG CD4
39 secondary syphilis 10.7 CD8A CD40LG CD4
40 pustulosis palmaris et plantaris 10.7 TNF CD40LG CCR6
41 selective immunoglobulin deficiency disease 10.7 ICOSLG CD8A CD40LG
42 posterior scleritis 10.7 TNF CRP ACE
43 west nile fever 10.7 CD8A CD40LG CD4
44 combat disorder 10.7 SERPINA3 CD8A CD4
45 subacute cutaneous lupus erythematosus 10.7 TNF ACE
46 ocular tuberculosis 10.7 IFNG CD4 ACE
47 klebsiella pneumonia 10.7 CRP CD40LG CCR6
48 acute dacryoadenitis 10.7 CRP ACE
49 necrotic uveal melanoma 10.7 IFNG CD8A
50 glossopharyngeal nerve paralysis 10.7 TNFRSF1B CD40LG

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CD40LG IL10 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 ACE IL10 IL2 NOD2 TNF TNFRSF1B

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACE CCR6 CD4 CD40LG CD8A IFNG
2 immune system MP:0005387 9.4 ACE CCR6 CD4 CD40LG CD8A CRP

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
2
Busulfan Approved, Investigational Phase 4 55-98-1 2478
3
Treosulfan Investigational Phase 4 299-75-2 9296
4 Immunologic Factors Phase 4
5 Alkylating Agents Phase 4
6 Immunosuppressive Agents Phase 4
7
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
8
Blinatumomab Approved, Investigational Phase 3 853426-35-4
9
rituximab Approved Phase 3 174722-31-7 10201696
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Ponatinib Approved, Investigational Phase 3 943319-70-8 24826799
12
Carmustine Approved, Investigational Phase 3 154-93-8 2578
13
Melphalan Approved Phase 3 148-82-3 460612 4053
14
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
15 Hemostatics Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Analgesics Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Antibodies, Bispecific Phase 3
20 Immunoglobulins Phase 3
21 Antibodies Phase 3
22 Antibodies, Monoclonal Phase 3
23 Antineoplastic Agents, Immunological Phase 3
24 Etoposide phosphate Phase 3
25 Antirheumatic Agents Phase 3
26 Protein Kinase Inhibitors Phase 3
27 Anti-Infective Agents Phase 3
28 Antiviral Agents Phase 3
29 Antimetabolites Phase 3
30 Imatinib Mesylate Phase 3 220127-57-1 123596
31
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
33
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
34
Gemcitabine Approved Phase 2 95058-81-4 60750
35
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
36
Zanubrutinib Approved, Investigational Phase 1, Phase 2 1691249-45-2
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
39
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
40
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
41
Ifosfamide Approved Phase 2 3778-73-2 3690
42
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
43
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
44
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
45
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
46
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
47
carbamide peroxide Approved Phase 2 124-43-6
48
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
49 Dacetuzumab Investigational Phase 2 880486-59-9 9953592
50 Immunoglobulins, Intravenous Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
2 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
3 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
4 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
5 Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL Active, not recruiting NCT02393859 Phase 3 Blinatumomab;Conventional Consolidation Chemotherapy
6 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
7 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
8 A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT00435916 Phase 2 SGN-40
9 A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma Completed NCT01183949 Phase 1, Phase 2 AT7519M;Bortezomib
10 An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT01741792 Phase 2 Blinatumomab
11 Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome Completed NCT00001145 Phase 2 Bacteriophage;rhuCD40L;KLH
12 A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs) Completed NCT01667133 Phase 1, Phase 2 ponatinib - Phase 1;ponatinib - Phase 2
13 A Single-Arm Multicenter Phase II Study Preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01471782 Phase 1, Phase 2
14 An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed NCT01466179 Phase 2
15 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting. Recruiting NCT04309084 Phase 1, Phase 2
16 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Recruiting NCT03744676 Phase 2
17 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Recruiting NCT03373019 Phase 2 Chidamide combined with R-GDP
18 A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting NCT03162536 Phase 1, Phase 2 ARQ 531;ARQ 531
19 Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting NCT03349450 Phase 2 Cyclophosphamide 50mg
20 Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting NCT03016377 Phase 1, Phase 2 Rimiducid;Cyclophosphamide;Fludarabine
21 Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Recruiting NCT02690545 Phase 1, Phase 2
22 A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Active, not recruiting NCT02733042 Phase 1, Phase 2 Durvalumab;Lenalidomide;Rituximab;Ibrutinib;Bendamustine
23 SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype Active, not recruiting NCT03713320 Phase 2 Cobomarsen;Vorinostat
24 PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study Enrolling by invitation NCT03837457 Phase 2 Cobomarsen
25 A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Terminated NCT00529503 Phase 2 SGN-40;placebo;rituximab;etoposide;carboplatin;ifosfamide
26 A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant Terminated NCT02592876 Phase 2 denintuzumab mafodotin;rituximab;ifosfamide;carboplatin;etoposide
27 An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b Terminated NCT02855359 Phase 2 denintuzumab mafodotin;rituximab;cyclophosphamide;doxorubicin;vincristine;prednisone
28 A Phase II Study of SGN-30 in Combination With CHOP in Anaplastic Large Cell Lymphoma Terminated NCT00365274 Phase 2 Cyclophosphamide;Doxorubicin hydrochloride;vincristine sulfate;prednisone;SGN-30
29 A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM) Completed NCT00525447 Phase 1 SGN-40;lenalidomide;dexamethasone
30 A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma Completed NCT00103779 Phase 1 SGN-40 (anti-huCD40 mAb)
31 A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma Completed NCT00079716 Phase 1 SGN-40 (anti-huCD40 mAb)
32 A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors Completed NCT00725634 Phase 1
33 A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT00655837 Phase 1 SGN-40;rituximab;gemcitabine
34 A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant Recruiting NCT02658968 Phase 1 Betalutin
35 Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Recruiting NCT02663297 Phase 1 ATLCAR.CD30 cells
36 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
37 Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Recruiting NCT03602157 Phase 1 Bendamustine;Fludarabine
38 An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma Active, not recruiting NCT02112526 Phase 1 Acalabrutinib
39 Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors Completed NCT00701844
40 Phase II Trial to Assess the Efficacy of Low Radiation Dose of 20 Gy for the Treatment of Marginal Zone Lymphoma or Follicular Lymphoma Stage I-II Localized in the Stomach or the Duodenum Recruiting NCT04097067
41 An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients Available NCT01200017
42 Compassionate Use Administration of Autologous CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch No longer available NCT03594162 iC9-CAR19 cells;AP1903;Cyclophosphamide;Fludarabine

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

40
B Cells, T Cells, Myeloid, Bone Marrow, Bone, Kidney, Testes

Publications for Hypersensitivity Reaction Type Iv Disease

Articles related to Hypersensitivity Reaction Type Iv Disease:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Screening for Humoral Immunodeficiency in Patients with Community-Acquired Pneumonia. 61
30534641 2019
2
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. 61
28350808 2017
3
Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. 61
23245703 2013
4
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. 61
23161721 2012
5
Enhanced serological diagnosis of invasive meningococcal disease by determining anti-group C capsule IgM antibody by enzyme immunoassay. 61
16175899 2005
6
Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. 61
14652716 2004
7
A flow cytometry technique to study nuclear factor-kappa B (NFkappaB) translocation during human B cell activation. 61
14611907 2003
8
The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. 61
10091599 1999
9
Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. 61
9515164 1998
10
Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. 61
9488143 1997
11
11q13 rearrangement in B cell chronic lymphocytic leukemia. 61
9250825 1997
12
[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders]. 61
7561364 1995
13
[Nerve lesions in patients with immunoproliferative disorders]. 61
7561361 1995
14
[Various immunoproliferative disorders]. 61
7561367 1995
15
Effect of alpha IFN on unaggressive immunoproliferative disorders. 61
7758989 1995
16
Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia. 61
8181187 1994
17
Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. 61
7927989 1994
18
Paraproteinemic crystalloidal keratopathy: an ultrastructural study of two cases, including immunoelectron microscopy. 61
8122330 1993
19
Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. 61
8468490 1993
20
[Heavy chain diseases]. 61
8502962 1993
21
Atypical immunoproliferative disorders: when of age? 61
8506619 1993
22
Structurally abnormal immunoglobulins in human immunoproliferative disorders. 61
1571535 1992
23
The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. 61
2044234 1991
24
Detection of Epstein-Barr virus genomes in archival tissues by polymerase chain reaction. 61
2163603 1990
25
Immunoproliferative disorders: detection, prevention, and therapeutics. 61
2508454 1989
26
Systemic vasculitis in association with human immunodeficiency virus infection. 61
2655605 1989
27
The clinical significance of pure Bence Jones proteinuria at low concentration. 61
2929504 1989
28
Immunoregulation in clinical diseases: an overview. 61
2642769 1989
29
The clinical spectrum of pure Bence Jones proteinuria. A study of 66 patients. 61
3179959 1988
30
Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. 61
3265901 1988
31
Immunobeads test (antibody coated polyacrylamide beads) in the immunological characterization of lymphoproliferative disorders. 61
3502472 1987
32
Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth. 61
3111667 1987
33
Light chains and the kidney. 61
3102562 1987
34
Monoclonal antibodies (Mabs) in head and neck cancer. 61
3534285 1986
35
Human T4+ lymphocytes produce a phagocytosis-inducing factor (PIF) distinct from interferon-alpha and interferon-gamma. 61
2416812 1986
36
Deregulation of immunoglobulin expression: is this the main cause of Burkitt's lymphoma? 61
4058028 1985
37
Association of lymphocytic neoplasia and mesothelioma. 61
3967191 1985
38
Study of cell-surface markers in chronic lymphocytic leukaemia (CLL). 61
6205953 1984
39
Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. 61
6667410 1983
40
A study of familial factors in Alzheimer's disease. 61
6212094 1982
41
[Clinical indications for monitoring immunologic reactivity (immune status)]. 61
6996352 1980
42
[Kinetic and immunological considerations on the therapy of immunoproliferative disorders]. 61
375339 1979
43
Cryopathic gangrene with an IgM lambda cryoprecipitating cold agglutinin. 61
101298 1978
44
Waldenström-like immunocytic lymphoma with IgG serum M component. 61
410217 1977
45
Monoclonal immunoglobulin disorders: a report of 154 cases. 61
820198 1976
46
Reticulum cell sarcoma of the cecum and macroglobulinemia: a case report. 61
817088 1976
47
The excretion of tryptophan metabolites in patients with different forms of haemoblastosis. 61
1244082 1975
48
Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. 61
4216270 1974
49
Surface IgD in immunoproliferative disorders. 61
4218365 1974
50
Lymphocyte transformation in immunoproliferative disorders. 61
4114813 1972

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 TNFRSF1B TNF SERPINA3 NOD2 IL2 IL10
2
Show member pathways
13.67 TNFRSF1B TNF IL2 IL10 IFNG CD40LG
3
Show member pathways
13.34 TNFRSF1B TNF NOD2 IL2 IL10 IFNG
4
Show member pathways
13.24 TNFRSF1B TNF IL2 IL10 CD40LG CD4
5
Show member pathways
13.04 TNF IL2 IL10 IFNG CASP10 ACE
6
Show member pathways
12.75 TNF IL2 IL10 IFNG ICOSLG CD8A
7
Show member pathways
12.65 TNFRSF1B TNF IFNG CD40LG CD4
8
Show member pathways
12.59 TNF NOD2 IL2 IL10 IFNG CD4
9
Show member pathways
12.58 TNF IL2 IL10 IFNG CD4
10
Show member pathways
12.58 TNF IL2 IL10 IFNG CD8A CD40LG
11
Show member pathways
12.53 TNFRSF1B TNF IL2 IL10 IFNG ICOSLG
12 12.52 TNFRSF1B TNF IL2 IL10 IFNG CD8A
13
Show member pathways
12.37 IL2 ICOSLG CD40LG CD4
14
Show member pathways
12.34 TNFRSF1B TNF IL2 IL10 CCR6
15
Show member pathways
12.33 TNF SERPINA3 IL2 IFNG CRP
16
Show member pathways
12.25 TNF IL10 IFNG CD40LG
17 12.24 TNF NOD2 IL10 IFNG CASP10
18 12.12 ICOSLG CD8A CD40LG CD4
19
Show member pathways
11.98 IL2 IFNG CD8A CD4
20 11.97 TNFRSF1B TNF NOD2 CASP10
21
Show member pathways
11.95 TNF IL2 IL10 IFNG CD4
22 11.86 TNF IL2 IL10 IFNG CD8A CD4
23
Show member pathways
11.78 TNFRSF1B TNF CD40LG
24
Show member pathways
11.77 TNF IL2 IFNG CD40LG
25
Show member pathways
11.72 TNFRSF1B TNF CD40LG
26
Show member pathways
11.67 TNF IL2 IFNG CD40LG
27
Show member pathways
11.64 TNF IL2 IFNG CD8A
28 11.55 TNF IL2 IFNG
29
Show member pathways
11.55 TNFRSF1B TNF IFNG
30 11.55 TNF IL10 IFNG CD40LG
31 11.53 TNFRSF1B TNF IL10
32 11.52 TNF IL2 IFNG
33 11.5 IL2 IL10 IFNG CD4
34 11.4 CD8A CD40LG CD4
35 11.38 TNF IL10 IFNG
36 11.33 TNFRSF1B IL2 IFNG CD40LG
37 11.3 TNF IL2 IL10 IFNG CD8A CD4
38 11.24 IL2 IFNG CD4
39
Show member pathways
11.21 TNFRSF1B TNF IL2 IL10 IFNG
40 11.2 IL2 IL10 IFNG
41 11.07 TNF IL2 IL10 IFNG CD8A CD4
42 11.02 TNF IL2 IL10 IFNG CD4

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNFRSF1B TNF SERPINA3 IL2 IL10 IFNG
2 extracellular space GO:0005615 9.61 TNF SERPINA3 MIR155 IL2 IL10 IFNG
3 external side of plasma membrane GO:0009897 9.23 TNF ICOSLG CD8A CD40LG CD4 CCR6

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.04 IL2 IFNG ICOSLG CD8A CD4
2 inflammatory response GO:0006954 10 TNFRSF1B TNF SERPINA3 CRP CD40LG
3 regulation of immune response GO:0050776 9.95 ICOSLG CD8A CD40LG BTNL2
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNF NOD2 CD4 CASP10
5 cell surface receptor signaling pathway GO:0007166 9.92 TNFRSF1B IFNG CD8A CD4 CASP10
6 positive regulation of protein phosphorylation GO:0001934 9.91 TNF IL2 IFNG CD4
7 cellular response to lipopolysaccharide GO:0071222 9.9 TNFRSF1B TNF NOD2 IL10
8 cytokine-mediated signaling pathway GO:0019221 9.85 TNFRSF1B TNF IL2 IL10 CD4
9 negative regulation of inflammatory response GO:0050728 9.84 TNFRSF1B MIR155 IL2 IL10
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 TNF IL2 IFNG
11 humoral immune response GO:0006959 9.8 TNF IFNG CCR6
12 T cell activation GO:0042110 9.76 ICOSLG CD8A CD4
13 extrinsic apoptotic signaling pathway GO:0097191 9.72 TNFRSF1B TNF IFNG
14 negative regulation of amyloid-beta clearance GO:1900222 9.67 TNF IFNG
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL10 IFNG
16 negative regulation of interleukin-8 production GO:0032717 9.66 MIR155 IL10
17 negative regulation of lipid storage GO:0010888 9.65 TNF CRP
18 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.64 TNF IFNG
19 endothelial cell apoptotic process GO:0072577 9.63 TNF IL10
20 negative regulation of vascular wound healing GO:0061044 9.63 TNF MIR155
21 positive regulation of cytokine secretion GO:0050715 9.61 TNF IL10 IFNG
22 negative regulation of cytokine production involved in immune response GO:0002719 9.59 TNF IL10
23 negative regulation of bicellular tight junction assembly GO:1903347 9.58 TNF MIR155
24 positive regulation of activated T cell proliferation GO:0042104 9.58 MIR155 IL2 ICOSLG
25 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.56 TNF IL10
27 positive regulation of inflammatory response GO:0050729 9.56 TNF MIR155 IL2 IFNG
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IFNG
29 receptor biosynthetic process GO:0032800 9.49 TNF IL10
30 regulation of cytokine secretion involved in immune response GO:0002739 9.48 TNFRSF1B MIR155
31 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.33 TNFRSF1B TNF IFNG
33 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
34 immune response GO:0006955 9.28 TNFRSF1B TNF IL2 IL10 IFNG CD8A
35 positive regulation of T cell proliferation GO:0042102 9.26 IL2 CD40LG CD4 BTNL2

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 TNF IL2 IL10 IFNG CD40LG

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....